|
286 Companies |
|
367 Products |
|
367 Products |
|
179 Mechanisms of Action |
|
18 Trials |
|
3665 News |
|
| «12...66676869707172737475767778» |
- || New P3 trial: Melanoma Margins Excision Trial (clinicaltrials.gov) - Oct 18, 2011
P3, N=10500, Not yet recruiting, Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust
- |||| imatinib / Generic mfg., hydroxyurea / Generic mfg.
Trial completion: Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) (clinicaltrials.gov) - Oct 18, 2011
P2, N=64, Completed, Sponsor: Duke University
Active, not recruiting --> Completed
- temozolomide / Generic mfg.
Trial completion: Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide (clinicaltrials.gov) - Oct 18, 2011
P1/2, N=26, Completed, Sponsor: AHS Cancer Control Alberta
Active, not recruiting --> Completed Recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 18, 2011
P1, N=35, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Recruiting --> Completed Active, not recruiting --> Completed
- AdCD40L / Uppsala University
New P1/2 trial, Gene therapy, Metastases: Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors (clinicaltrials.gov) - Oct 17, 2011
P1/2, N=30, Recruiting, Sponsor: Uppsala University
- BMS-936559 / BMS
Biomarker, New P1 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (clinicaltrials.gov) - Oct 17, 2011
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
- Enrollment closed: Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoing Radiotherapy (clinicaltrials.gov) - Oct 17, 2011
P=N/A, N=30, Active, not recruiting, Sponsor: AHS Cancer Control Alberta
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Vigil (gemogenovatucel-T) / Gradalis
New P2 trial, Tumor cell, Metastases: Phase II FANG (clinicaltrials.gov) - Oct 13, 2011
P2, N=15, Active, not recruiting, Sponsor: Gradalis, Inc.
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed: BO21990: A Study of Bevacizumab (Avastin (clinicaltrials.gov) - Oct 13, 2011
P3, N=921, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial completion: Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Oct 13, 2011
P2, N=41, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Azixa (verubulin) / Immune Pharma
Enrollment change: Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Oct 12, 2011
P2, N=5, Completed, Sponsor: Myrexis Inc.
Active, not recruiting --> Completed N=128 --> 5
- |||| Azixa (verubulin) / Immune Pharma
Trial completion: Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Oct 12, 2011
P2, N=56, Completed, Sponsor: Myrexis Inc.
N=128 --> 5 Active, not recruiting --> Completed
- Farydak (panobinostat) / Secura Bio
Trial withdrawal: CLBH589C: A Panobinostat Presurgery (clinicaltrials.gov) - Oct 10, 2011
P2, N=0, Withdrawn, Sponsor: Duke University
Active, not recruiting --> Completed Recruiting --> Withdrawn
- | Azedra (iobenguane I 131) / Lantheus
Trial termination: Efficacy and Safety of Ultratrace (clinicaltrials.gov) - Oct 10, 2011
P2, N=100, Terminated, Sponsor: Molecular Insight Pharmaceuticals, Inc.
Recruiting --> Withdrawn Not yet recruiting --> Terminated
- Trial termination, Metastases: Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma (clinicaltrials.gov) - Oct 10, 2011
P1, N=12, Terminated, Sponsor: Molecular Insight Pharmaceuticals, Inc.
Not yet recruiting --> Terminated Recruiting --> Terminated
- Caprelsa (vandetanib) / Sanofi
Enrollment change: Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma (clinicaltrials.gov) - Oct 10, 2011
P1, N=27, Completed, Sponsor: Annick Desjardins
Recruiting --> Terminated N=48 --> 27
- || New P3 trial: Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Oct 10, 2011
P3, N=159, Active, not recruiting, Sponsor: International Atomic Energy Agency
- ||||| ondansetron / Generic mfg., temozolomide / Generic mfg.
New P2 trial, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - Oct 10, 2011
P2, N=136, Recruiting, Sponsor: Katy Peters
- | Enrollment open: A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma (clinicaltrials.gov) - Oct 10, 2011
P2, N=45, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=48 --> 27 Not yet recruiting --> Recruiting
- Caprelsa (vandetanib) / Sanofi
Trial completion: Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma (clinicaltrials.gov) - Oct 10, 2011
P1, N=27, Completed, Sponsor: Annick Desjardins
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- erlotinib / Generic mfg., dasatinib / Generic mfg.
Trial completion: Ph I Dasatinib + Erlotinib in Recurrent MG (clinicaltrials.gov) - Oct 10, 2011
P1, N=47, Completed, Sponsor: Duke University
Active, not recruiting --> Completed Recruiting --> Completed
- | Proleukin (aldesleukin) / Iovance Biotherap
Trial completion: Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma (clinicaltrials.gov) - Oct 10, 2011
P3, N=185, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment open, PARP Biomarker, IO biomarker: CRUK-CR0901-11: Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma (clinicaltrials.gov) - Oct 6, 2011
P1, N=34, Recruiting, Sponsor: Cancer Research UK
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed: Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy (clinicaltrials.gov) - Oct 5, 2011
P=N/A, N=12, Active, not recruiting, Sponsor: Loma Linda University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, ITC-6146RO / IntoCell
Enrollment change: Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma (clinicaltrials.gov) - Oct 2, 2011
P2, N=4, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting N=10 --> 4
- ITC-6146RO / IntoCell
Enrollment change: Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma (clinicaltrials.gov) - Oct 2, 2011
P1, N=38, Completed, Sponsor: St. Jude Children's Research Hospital
N=10 --> 4 N=12 --> 38
- | New P2 trial: More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery (clinicaltrials.gov) - Oct 2, 2011
P2, N=60, Recruiting, Sponsor: Emory University
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, ITC-6146RO / IntoCell
Trial completion: Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma (clinicaltrials.gov) - Oct 2, 2011
P2, N=4, Completed, Sponsor: St. Jude Children's Research Hospital
N=12 --> 38 Active, not recruiting --> Completed
- carboplatin / Generic mfg., vincristine / Generic mfg.
Trial completion: Carboplatin Plus Vincristine in Treating Children With Retinoblastoma (clinicaltrials.gov) - Oct 2, 2011
P2, N=25, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ITC-6146RO / IntoCell
Trial completion: Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma (clinicaltrials.gov) - Oct 2, 2011
P1, N=38, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Kinenza (enzastaurin) / Denovo, Aytu BioPharma
New P1 trial: A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas (clinicaltrials.gov) - Sep 29, 2011
P1, N=58, Completed, Sponsor: Eli Lilly and Company
- netazepide (YF476) / Trio Medicines
New P2 trial: YF476 and Type I Gastric Carcinoids (Norway) (clinicaltrials.gov) - Sep 27, 2011
P2, N=10, Enrolling by invitation, Sponsor: Trio Medicines Ltd.
- Trial completion: Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas (clinicaltrials.gov) - Sep 27, 2011
P=N/A, N=30, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: BEAM: A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma (clinicaltrials.gov) - Sep 26, 2011
P2, N=214, Completed, Sponsor: Genentech
Recruiting --> Completed Active, not recruiting --> Completed
- | Tavo (tavokinogene telsaplasmid) / OncoSec
New P2 trial: IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer (clinicaltrials.gov) - Sep 25, 2011
P2, N=15, Recruiting, Sponsor: OncoSec Medical Incorporated
- | New P2 trial: A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma (clinicaltrials.gov) - Sep 22, 2011
P2, N=45, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Ontak (denileukin diftitox) / Eisai, TSD Japan
Trial completion: Phase II Trial of Ontak With Metastatic Melanoma (clinicaltrials.gov) - Sep 21, 2011
P2, N=69, Completed, Sponsor: James Graham Brown Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- temozolomide / Generic mfg., dichloroacetate topical / Generic mfg.
Trial withdrawal: Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Sep 20, 2011
P1, N=0, Withdrawn, Sponsor: AHS Cancer Control Alberta
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Trial withdrawal: Minimized Time to Beam in Patients With High Grade Gliomas (clinicaltrials.gov) - Sep 20, 2011
P=N/A, N=0, Withdrawn, Sponsor: AHS Cancer Control Alberta
Not yet recruiting --> Withdrawn Not yet recruiting --> Withdrawn
- temozolomide / Generic mfg., dichloroacetate topical / Generic mfg.
Enrollment change: Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Sep 20, 2011
P1, N=0, Withdrawn, Sponsor: AHS Cancer Control Alberta
Not yet recruiting --> Withdrawn N=15 --> 0
- Enrollment change: Minimized Time to Beam in Patients With High Grade Gliomas (clinicaltrials.gov) - Sep 20, 2011
P=N/A, N=0, Withdrawn, Sponsor: AHS Cancer Control Alberta
N=15 --> 0 N=25 --> 0
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment change: Non Interventional Post Marketing Programme in Neuroendocrine Tumours (clinicaltrials.gov) - Sep 19, 2011
P=N/A, N=40, Completed, Sponsor: Ipsen
N=25 --> 0 N=50 --> 40
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment closed: A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma (clinicaltrials.gov) - Sep 19, 2011
P1, N=31, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
N=50 --> 40 Recruiting --> Active, not recruiting
- Enrollment closed, Biopsy: Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma (clinicaltrials.gov) - Sep 18, 2011
P1, N=100, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| pidilizumab (CT-011) / CureTech
New P2 trial, Metastases: Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma (clinicaltrials.gov) - Sep 14, 2011
P2, N=103, Completed, Sponsor: CureTech Ltd
- cyclophosphamide / Generic mfg.
New P1 trial, Combination therapy: Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma (clinicaltrials.gov) - Sep 14, 2011
P1, N=19, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Avastin (bevacizumab) / Roche
New P1 trial: Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Sep 14, 2011
P1, N=18, Recruiting, Sponsor: Emory University
- ||||| Tafinlar (dabrafenib) / Novartis
Enrollment closed, Metastases: A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma (clinicaltrials.gov) - Sep 14, 2011
P3, N=200, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines (clinicaltrials.gov) - Sep 14, 2011
P1, N=18, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Inlyta (axitinib) / Pfizer
New P2 trial: A Study of Axitinib in Advanced Carcinoid Tumors (clinicaltrials.gov) - Sep 13, 2011
P2, N=30, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute